Amedisys Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive
November 7, 2016 7:48 AM ESTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $47.00, calling the sell-off after the COO resigned 'excessively overdone'.
Analyst Sheryl Skolnick commented, "AMED's shares dove Friday in concert with another C-Suite change at the... More
Amedisys (AMED) PT Cut to $47 at Mizuho Following Results
November 4, 2016 7:05 AM EDTMizuho Securities analyst Sheryl Skolnick reiterated a Neutral rating and lowered her price target on Amedisys (NASDAQ: AMED) to $47.00 following results.
Skolnick commented, "What the new team has done for AMED in a very short period of time seems close to a miracle... More
